• Frontida Expands Testing Capabilities contractpharma
    February 03, 2021
    ​Frontida BioPharm has launched its new Category 1 (CAT.ONE) in vitro testing and evaluation services to support development and regulatory approvals for abuse-deterrent formulations of pain management and Central Nervous System (CNS) targeted therapies.
PharmaSources Customer Service